NEK11 Inhibitors
1 drugsAbout NEK11
NEK11, or NIMA-related kinase 11, is a protein kinase involved in regulating cellular processes through phosphorylation. Its dysregulation is often implicated in disease, making it a target of interest, particularly in oncology.
NEK11 is a therapeutic target in oncology, though there is currently no genetic evidence data available linking it to specific diseases. Targeting NEK11 has the potential to disrupt cancer cell growth and survival.
NEK11 is targeted by one FDA-approved drug, TAFINLAR (Novartis), a small molecule with 4 indications in oncology. TAFINLAR was first approved in 2013, and no other drugs have been approved since.
Top NEK11 Drugs
Novartis is the only company with an approved drug targeting NEK11.
Low competition suggests a potential first-mover advantage, but also indicates higher risk due to lack of validation by others.
NEK11 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets NEK11, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches like antibodies or PROTACs.
NEK11 Clinical Trials 93 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on NEK11. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 33 | 12 | 13 | 6 | 48% |
| Phase 2 | 49 | 15 | 12 | 22 | 56% |
| Phase 3 | 8 | 4 | 1 | 3 | 80% |
| Phase 4 | 3 | 0 | 0 | 3 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
NEK11 Drug Approval Timeline (2013 - 2013)
The first and only drug targeting NEK11, TAFINLAR, was approved in 2013.
The lack of recent approvals suggests saturation or challenges in developing further NEK11-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 47 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on NEK11. A trial counts if an approved drug acting on NEK11 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.